1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > 2013 Oncology Research Review

2013 Oncology Research Review

  • December 2013
  • -
  • BCC Research
  • -
  • 144 pages

FOREWORD

Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. These Research Reviews include portions of several market research reports that were published in 2013, and are an efficient way for market professionals to keep up with the general market developments of 2013.
Please note that page references in the text are to pages in the original, complete report, and do not reflect the actual page numbers in this Research Review.

This 2013 Pharmaceuticals Research Review includes excerpts from the following reports:
• HLC142A Therapies and Diagnostics for Uterine Cancer.
• HLC141A Therapies and Diagnostics for Cervical Cancer.
• PHM113A Prevention and Treatment of Prostate Cancer: Technologies and Global Markets.
• HLC143A Therapies and Diagnostics for Ovarian Cancer.
• PHM116A Drugs and Diagnostics for Hematological Disorders: Global Market.

REPORT HIGHLIGHTS

• The global market for uterine cancer treatments and diagnostics reached $17.4 billion in 2012. This market is expected to grow to nearly $17.8 billion in 2013 and then to nearly $21.6 billion in 2018, a compound annual growth rate (CAGR) of 3.9% over the five-year period from 2013 to 2018.
• The global cervical cancer market for drugs and diagnostics was $11.3 billion in 2012 and is expected to grow from $11.6 billion in 2013 to $15.6 billion by 2018, a compound annual growth rate (CAGR) of 6.1%.
• The global market for the prevention and treatment of prostate cancer was valued at $26.1 billion in 2011 and should reach nearly $29.3 billion in 2012. Total market value is expected to reach $50.3 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 11.4%.

Table Of Contents

2013 Oncology Research Review
TABLE OF CONTENTS

CHAPTER 1 ABOUT BCC RESEARCH REVIEWS 2

FOREWORD 2

CHAPTER 2 THERAPIES AND DIAGNOSTICS FOR UTERINE CANCER (REPORT HLC142A) 4

INTRODUCTION 4
STUDY GOALS AND OBJECTIVES 4
REASONS FOR DOING THIS STUDY 4
INTENDED AUDIENCE 4
SCOPE OF THE STUDY 5
METHODOLOGY 5
INFORMATION SOURCES 6
ABOUT THE AUTHOR 6
RELATED BCC RESEARCH REPORTS 6
SUMMARY 6
TABLE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS,
GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 8
FIGURE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS,
GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 9
OVERVIEW 9
CANCER 9
TABLE 2 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER 10
GYNECOLOGIC CANCERS 11
ENDOMETRIAL/UTERINE CANCER 11
TABLE 3 KEY CLINICAL FEATURES OF UTERINE CANCER 12
TABLE 4 HISTOLOGY OF ADENOCARCINOMA 13
Causes/Risk Factors 13
Hormone Factors 14
TABLE 5 RISK FACTORS 15
Estrogen 15
Estrogen Therapy 15
Oral Contraceptives 16
Total Number of Menstrual Cycles 16
Pregnancy 16
Obesity 16
Treatment with Tamoxifen 17
Ovarian Tumors 17
Polycystic Ovarian Syndrome 17
Use of an Intrauterine Device 17
Age 17
Diet and Exercise 18
Diabetes 18
Genetics 18
TABLE 6 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC) 18
Breast Cancer 19
Prior Pelvic Radiation Therapy 19
Endometrial Hyperplasia 19
Classification 19
Carcinoma 19
TABLE 7 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC
GROUPS 19
Sarcoma 20
TABLE 8 CARCINOMA OF THE ENDOMETRIUM 21
Endometrial Cancer Symptoms 21
TABLE 9 SIGNS AND SYMPTOMS 22
Diagnosis 22
Clinical Evaluation 22
TABLE 10 UTERINE CANCER: DIAGNOSIS 22
Tests 23
TABLE 11 DIAGNOSTIC TESTS 23
TABLE 12 STAGES OF ENDOMETRIAL CANCER 23
Pathology 24
Treatment 24
TABLE 13 TREATMENT DEPENDS UPON THE STAGE 25
Uterine Cancer Treatment is Based on Several Important Factors 25
Prognosis 26
Survival Rates 26
TABLE 14 FIVE-YEAR SURVIVAL RATES (%) 27
TABLE 15 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%) 28
Epidemiology 28
Complications 28
Prevention 28

CHAPTER 3 THERAPIES AND DIAGNOSTICS FOR CERVICAL CANCER (REPORT HLC141A) 30

INTRODUCTION 30
STUDY GOALS AND OBJECTIVES 30
REASONS FOR DOING THIS STUDY 30
INTENDED AUDIENCE 30
SCOPE OF THE STUDY 31
METHODOLOGY 31
INFORMATION SOURCES 31
ABOUT THE AUTHOR 32
RELATED BCC RESEARCH REPORTS 32
SUMMARY 32
TABLE 16 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS,
THROUGH 2018 ($ MILLIONS) 33
FIGURE 2 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS,
2012-2018 ($ MILLIONS) 33
OVERVIEW 34
TABLE 17 MAIN TYPES OF CANCER AND MORTALITY 34
FIGURE 3 MAIN TYPES OF CANCER AND MORTALITY 34
TABLE 18 CANCER: KEY FACTS 35
TABLE 19 PREVENTION STRATEGIES 36
EARLY DETECTION 36
EARLY DIAGNOSIS 36
SCREENING 36
TABLE 20 CURRENT SCREENING METHODS 37
CANCER TREATMENT 37
TABLE 21 NONCOMMUNICABLE DISEASES ACTION PLAN 38
CERVICAL CANCER 38
TABLE 22 HISTORY 38
CERVICAL CANCER RESEARCH AND TREATMENT 39
Sentinel Lymph Node Biopsy 39
Human Papillomavirus (HPV) Vaccines 39
Targeted Therapy 40
Hyperthermia 40
Drug Treatment of Precancers 40
SYMPTOMS 40
TABLE 23 CERVICAL CANCER SYMPTOMS 40
TABLE 24 ADVANCED CERVICAL CANCER SYMPTOMS 41
DIAGNOSIS 41
TABLE 25 DIAGNOSIS OF CERVICAL CANCER 41
TABLE 26 RISK FACTORS FOR CERVICAL CANCER 42
TREATMENT 42
TABLE 27 CERVICAL CANCER STAGING 42
PROGNOSIS 43

CHAPTER 4 PREVENTION AND TREATMENT OF PROSTATE CANCER: TECHNOLOGIES AND GLOBAL MARKETS (REPORT PHM113A) 45

INTRODUCTION 45
STUDY GOALS AND OBJECTIVES 45
REASONS FOR DOING THIS STUDY 45
INTENDED AUDIENCE 45
SCOPE OF THE STUDY 46
METHODOLOGY 46
INFORMATION SOURCES 47
ABOUT THE AUTHOR 47
RELATED BCC RESEARCH REPORTS 47
SUMMARY 47
TABLE 28 GLOBAL PROSTATE CANCER MARKET, THROUGH 2017 ($ MILLIONS) 49
FIGURE 4 GLOBAL PROSTATE CANCER MARKET, 2010-2017 ($ MILLIONS) 49
OVERVIEW 50
U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS 51
TABLE 29 U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008 52
BIOLOGY OF PROSTATE CANCER 53
PROSTATE GLAND 53
PROSTATE GLAND FUNCTION 54
GROWTH OF THE PROSTATE GLAND 54
TYPES OF PROSTATE CANCER 55
PRECANCEROUS CONDITIONS OF THE PROSTATE 55
PROSTATIC INTRAEPITHELIAL NEOPLASIA (PIN) 55
PROLIFERATIVE INFLAMMATORY ATROPHY (PIA) 56
PROSTATE CANCER DEVELOPMENT 56
AGING 56
MECHANISMS OF DISEASE DEVELOPMENT PATHOPHYSIOLOGY 57
FAMILY HISTORY 57
ENVIRONMENTAL FACTORS 58
EPIDEMIOLOGY AND RISK FACTORS 58
HORMONES 58
GROWTH FACTORS 59
TABLE 30 GROWTH FACTORS IMPLICATED IN PROSTATE CANCER 60
GENETICS 61
TABLE 31 PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI 61
MOLECULAR MECHANISMS OF PROSTATE CANCER 62
TABLE 32 IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER 62
The Androgen Receptor 63
PTEN 63
p53 63
GSTP GENES 64
TABLE 33 MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION 64
PROSTATE-SPECIFIC ANTIGEN 66
CAVEOLIN-1 66
EMSY 66
AMACR 66
KLF6 66
NBS1 67
CHEK2 67
MISMATCH REPAIR GENES 67
HOXB13 67
BRCA1 AND BRCA2 68
HEREDITARY PROSTATE CANCER 68
PROSTATE CANCER PREVENTION AND TREATMENT 68
CONCLUSIONS 70

CHAPTER 5 THERAPIES AND DIAGNOSTICS FOR OVARIAN CANCER (REPORT HLC143A) 73

INTRODUCTION 73
STUDY GOALS AND OBJECTIVES 73
REASONS FOR CONDUCTING THIS STUDY 73
INTENDED AUDIENCE 73
SCOPE OF THE STUDY 74
METHODOLOGY 74
INFORMATION SOURCES 74
ABOUT THE AUTHOR 75
RELATED BCC RESEARCH REPORTS 75
SUMMARY 75
TABLE 34 OVARIAN CANCER DRUGS AND DIAGNOSTICS—GLOBAL MARKETS,
THROUGH 2018 ($ MILLIONS) 76
FIGURE 5 OVARIAN CANCER DRUGS AND DIAGNOSTICS: GLOBAL MARKETS,
2012-2018 ($ MILLIONS) 76
OVERVIEW 77
OVARIAN CANCERS 78
TABLE 35 OVARIAN CANCER FACTS 78
TABLE 36 TYPES OF OVARIAN CANCERS 78
EPITHELIAL TUMORS 78
GERM CELL TUMORS 79
STROMAL TUMORS 79
METASTASIS 79
TABLE 37 OVARIAN TUMORS METASTASIS 79
OVARIAN DISORDERS 79
RISK FACTORS 80
TABLE 38 MAIN RISK FACTORS FOR OVARIAN CANCER 80
TABLE 39 HIGH-RISK FACTORS 81
PREVENTION 81
TABLE 40 PREVENTIVE FACTORS 82
PREVENTIVE STRATEGIES FOR HIGH-RISK WOMEN 82
SYMPTOMS 83
TABLE 41 OVARIAN CANCER SYMPTOMS 83
SIGNS OF CANCER 83
DIAGNOSIS AND SYMPTOM PROGRESSION 84
Early Detection 84
DIAGNOSIS 85
TUMOR MARKERS 85
VITAMIN D AND OVARIAN CANCER 85
PROGNOSIS 86
PROGNOSIS BY STAGE 86
TREATMENT 86
CHEMOTHERAPY 86
TARGETED THERAPY 87
IMMUNOTHERAPY 87
RESEARCH AND NEW DEVELOPMENTS 87
CONCLUSIONS 88

CHAPTER 6 DRUGS AND DIAGNOSTICS FOR HEMATOLOGICAL DISORDERS: GLOBAL MARKET (REPORT PHM116A) 90

INTRODUCTION 90
STUDY GOALS AND OBJECTIVES 90
REASONS FOR DOING THIS STUDY 90
INTENDED AUDIENCE 90
SCOPE OF THE STUDY 91
METHODOLOGY 91
INFORMATION SOURCES 92
ABOUT THE AUTHOR 92
RELATED BCC RESEARCH REPORTS 92
SUMMARY 92
TABLE 42 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL
MARKETS, THROUGH 2017 ($ MILLIONS) 94
FIGURE 6 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL
MARKETS, 2010-2017 ($ MILLIONS) 94
OVERVIEW 94
TABLE 43 KEY BLOOD DISORDERS 95
TABLE 44 MALIGNANT BLOOD DISORDERS 95
TABLE 45 NON-MALIGNANT BLOOD DISORDERS 96
BLOOD DISEASES 97
TABLE 46 TYPE OF BLOOD CELLS AND FUNCTIONS 97
TABLE 47 BLOOD CELLS AND FUNCTION 98
BLOOD DISORDERS 98
ANEMIA 98
Types of Anemia 98
TABLE 48 THREE MAJOR TYPES OF ANEMIA 98
TABLE 49 ANEMIA: MAJOR CATEGORIES 99
TABLE 50 SYMPTOMS OF ANEMIA 100
TABLE 51 TYPES OF ANEMIA 101
MEGALOBLASTIC ANEMIAS 102
Cobalamin Deficiency 102
TABLE 52 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY 103
Folate Deficiency 103
TABLE 53 DRUGS: CAUSE OF FOLATE DEFICIENCY 104
DIAGNOSTIC TESTS 104
Schilling Test 104
Serum Ferritin and Iron Studies 105
Other Tests 105
TREATMENT 105
HEMOGLOBIN DISORDERS 106
THALASSEMIA 106
SICKLE-CELL ANEMIA 106
TABLE 54 KEY FACTS 107
Causes 107
World Health Organization's Resolutions 108
HEMOLYTIC ANEMIA 108
TABLE 55 LAB TESTS FOR ANEMIA 108
Treatment 109
Anemia Medications 109
HEMOSTASIS 110
HEMOSTASIS: STEPS OF MECHANISM 110
TABLE 56 HEMOSTASIS: THREE MAJOR STEPS 111
TYPES OF HEMOSTASIS 111
Hemostasis in Emergency Medicine 111
ARTIFICIAL HEMOSTASIS 112
TABLE 57 DRUGS THAT EFFECT ACTIVITY OF PLATELETS 113
TABLE 58 ANTICOAGULANTS THAT ACT ON THROMBIN 113
BLEEDING DISORDERS 114
TABLE 59 BLEEDING DISORDERS 114
TABLE 60 BLEEDING DISORDERS: SYMPTOMS 115
TABLE 61 SIGNS AND TESTS 115
HEMOPHILIA 115
TABLE 62 KEY CHARACTERISTICS: HEMOPHILIA 116
CLASSIFICATION 117
HISTORICAL BACKGROUND 117
The Clotting Cascade 118
Hemorrhage 118
Natural Inhibitors 119
ACQUIRED HEMOPHILIA 119
FORMS OF HEMOPHILIA 119
Symptoms and Complications 120
Diagnosis 120
Genetic Testing 121
Treatment 121
TABLE 64 MEDICATIONS FOR TREATING HEMOPHILIA 125
Factor VIII Products 125
TABLE 65 FACTOR VIII PRODUCTS 126
Antifibrinolytics 126
TABLE 66 ANTIFIBRINOLYTICS 126
Antihemophilic Agents 126
TABLE 67 ANTIHEMOPHILIC AGENTS 127
Coagulation Factor VIIa, Recombinants 127
Factor VIIa, Recombinant (NovoSeven) 127
Monoclonal Antibodies 127
Rituximab (Rituxan) 128
VON WILLEBRAND DISEASE 128
Symptoms and Diagnosis 128
Treatment 128
THROMBOPHILIA 129
Diagnosis and Treatment 129
THROMBOSIS 130
TABLE 68 FORMATION OF THROMBUS 131
DEEP VEIN THROMBOSIS AND TREATMENT 131
Heparin 131
Warfarin 132
SUPERFICIAL THROMBOPHLEBITIS 132
DEEP VENOUS THROMBOSIS 132
Tests 132
Treatment 133
Surgery 133
HEREDITARY HEMORRHAGIC TELANGIECTASIA 133
ERYTHROCYTOSIS 134
ABSOLUTE POLYCYTHEMIA 134
Primary Polycythemia 134
Secondary Polycythemia 135
Chuvash Polycythemia 135
Relative Polycythemia 136
WHITE BLOOD CELL DISORDERS 136
TREATMENT 136
NEUTROPENIA 137
Causes 137
TABLE 69 CAUSES FOR NEUTROPENIA 137
Symptoms and Diagnosis 138
Treatment 138
NEUTROPHILIA 139
BLOOD DISORDERS AFFECTING PLATELETS 139
TABLE 70 WHITE BLOOD CELLS AND DISEASES 139
THROMBOCYTOPENIA 140
Treatment 140
LYMPHOCYTOPENIA 140
Treatment 141
LYMPHOCYTIC LEUKOCYTOSIS 141
MONOCYTOSIS 141
THROMBOCYTHEMIA AND THROMBOCYTOSIS 141
Primary Thrombocythemia 141
Secondary Thrombocytosis 142
TABLE 71 CAUSE OF SECONDARY THROMBOCYTOSIS 143
Symptoms 143
TABLE 72 DIAGNOSTIC TESTS 144
Treatment 144
TABLE 73 MEDICINES FOR THROMBOCYTHEMIA 145
THROMBOCYTOPENIA 145
Causes 145
TABLE 74 CAUSES OF THROMBOCYTOPENIA 146
RARE CONDITIONS THAT CAUSE BLOOD CLOTS 147
Signs and Symptoms 147
TABLE 75 SIGNS OF EXTERNAL BLEEDING 147
Tests 148
Treatment 148
SEVERE THROMBOCYTOPENIA 148
EOSINOPHILS AND DISORDERS 148
TABLE 76 COMMON DRUGS TO TREAT EOSINOPHILIA 149
BASOPHILS AND DISORDERS 149
PLASMA CELL DISORDERS 150



LIST OF TABLES

TABLE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS, GLOBAL
MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 8
TABLE 2 LIFESTYLE CHANGES THAT HELP REDUCE THE PREVALENCE OF CANCER 10
TABLE 3 KEY CLINICAL FEATURES OF UTERINE CANCER 12
TABLE 4 HISTOLOGY OF ADENOCARCINOMA 13
TABLE 5 RISK FACTORS 15
TABLE 6 GENES: CAUSE OF HEREDITARY NONPOLYPOSIS COLON CANCER (HNPCC) 18
TABLE 7 ENDOMETRIAL CARCINOMAS CLASSIFIED INTO TWO PATHOGENETIC
GROUPS 19
TABLE 8 CARCINOMA OF THE ENDOMETRIUM 21
TABLE 9 SIGNS AND SYMPTOMS 22
TABLE 10 UTERINE CANCER: DIAGNOSIS 22
TABLE 11 DIAGNOSTIC TESTS 23
TABLE 12 STAGES OF ENDOMETRIAL CANCER 23
TABLE 13 TREATMENT DEPENDS UPON THE STAGE 25
TABLE 14 FIVE-YEAR SURVIVAL RATES (%) 27
TABLE 15 UTERINE CARCINOSARCOMA: FIVE-YEAR SURVIVAL RATES BY STAGE (%) 28
TABLE 16 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS,
THROUGH 2018 ($ MILLIONS) 33
TABLE 17 MAIN TYPES OF CANCER AND MORTALITY 34
TABLE 18 CANCER: KEY FACTS 35
TABLE 19 PREVENTION STRATEGIES 36
TABLE 20 CURRENT SCREENING METHODS 37
TABLE 21 NONCOMMUNICABLE DISEASES ACTION PLAN 38
TABLE 22 HISTORY 38
TABLE 23 CERVICAL CANCER SYMPTOMS 40
TABLE 24 ADVANCED CERVICAL CANCER SYMPTOMS 41
TABLE 25 DIAGNOSIS OF CERVICAL CANCER 41
TABLE 26 RISK FACTORS FOR CERVICAL CANCER 42
TABLE 27 CERVICAL CANCER STAGING 42
TABLE 28 GLOBAL PROSTATE CANCER MARKET, THROUGH 2017 ($ MILLIONS) 49
TABLE 29 U.S. PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS, 2008 52
TABLE 30 GROWTH FACTORS IMPLICATED IN PROSTATE CANCER 60
TABLE 31 PROPOSED PROSTATE CANCER SUSCEPTIBILITY LOCI 61
TABLE 32 IMPORTANT GENES IN THE DEVELOPMENT OF PROSTATE CANCER 62
TABLE 33 MUTATED GENES AND ABNORMAL PROTEIN EXPRESSION 64
TABLE 34 OVARIAN CANCER DRUGS AND DIAGNOSTICS—GLOBAL MARKETS,
THROUGH 2018 ($ MILLIONS) 76
TABLE 35 OVARIAN CANCER FACTS 78
TABLE 36 TYPES OF OVARIAN CANCERS 78
TABLE 37 OVARIAN TUMORS METASTASIS 79
TABLE 38 MAIN RISK FACTORS FOR OVARIAN CANCER 80
TABLE 39 HIGH-RISK FACTORS 81
TABLE 40 PREVENTIVE FACTORS 82
TABLE 41 OVARIAN CANCER SYMPTOMS 83
TABLE 42 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL
MARKETS, THROUGH 2017 ($ MILLIONS) 94
TABLE 43 KEY BLOOD DISORDERS 95
TABLE 44 MALIGNANT BLOOD DISORDERS 95
TABLE 45 NON-MALIGNANT BLOOD DISORDERS 96
TABLE 46 TYPE OF BLOOD CELLS AND FUNCTIONS 97
TABLE 47 BLOOD CELLS AND FUNCTION 98
TABLE 48 THREE MAJOR TYPES OF ANEMIA 98
TABLE 49 ANEMIA: MAJOR CATEGORIES 99
TABLE 50 SYMPTOMS OF ANEMIA 100
TABLE 51 TYPES OF ANEMIA 101
TABLE 52 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY 103
TABLE 53 DRUGS: CAUSE OF FOLATE DEFICIENCY 104
TABLE 54 KEY FACTS 107
TABLE 55 LAB TESTS FOR ANEMIA 108
TABLE 56 HEMOSTASIS: THREE MAJOR STEPS 111
TABLE 57 DRUGS THAT EFFECT ACTIVITY OF PLATELETS 113
TABLE 58 ANTICOAGULANTS THAT ACT ON THROMBIN 113
TABLE 59 BLEEDING DISORDERS 114
TABLE 60 BLEEDING DISORDERS: SYMPTOMS 115
TABLE 61 SIGNS AND TESTS 115
TABLE 62 KEY CHARACTERISTICS: HEMOPHILIA 116
TABLE 64 MEDICATIONS FOR TREATING HEMOPHILIA 125
TABLE 65 FACTOR VIII PRODUCTS 126
TABLE 66 ANTIFIBRINOLYTICS 126
TABLE 67 ANTIHEMOPHILIC AGENTS 127
TABLE 68 FORMATION OF THROMBUS 131
TABLE 69 CAUSES FOR NEUTROPENIA 137
TABLE 70 WHITE BLOOD CELLS AND DISEASES 139
TABLE 71 CAUSE OF SECONDARY THROMBOCYTOSIS 143
TABLE 72 DIAGNOSTIC TESTS 144
TABLE 73 MEDICINES FOR THROMBOCYTHEMIA 145
TABLE 74 CAUSES OF THROMBOCYTOPENIA 146
TABLE 75 SIGNS OF EXTERNAL BLEEDING 147
TABLE 76 COMMON DRUGS TO TREAT EOSINOPHILIA 149



LIST OF FIGURES

FIGURE 1 UTERINE/ENDOMETRIAL CANCER: TREATMENT AND DIAGNOSTICS,
GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 9
FIGURE 2 CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS,
2012-2018 ($ MILLIONS) 33
FIGURE 3 MAIN TYPES OF CANCER AND MORTALITY 34
FIGURE 4 GLOBAL PROSTATE CANCER MARKET, 2010-2017 ($ MILLIONS) 49
FIGURE 5 OVARIAN CANCER DRUGS AND DIAGNOSTICS: GLOBAL MARKETS,
2012-2018 ($ MILLIONS) 76
FIGURE 6 HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS: GLOBAL
MARKETS, 2010-2017 ($ MILLIONS) 94

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Hemophilia Treatment Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Hemophilia Treatment Drugs Market: Overview Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary ...

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

Apheresis Market by Product, Procedure, Application, Technology - Global Forecast to 2021

  • $ 5650
  • Industry report
  • February 2017
  • by MarketsandMarkets

The global apheresis market is projected to reach USD 2.06 billion by 2021, at a CAGR of 7.7% during the forecast period of 2016 to 2021. Growth in this market is majorly driven by the rising prevalence ...

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

Epiomic Epidemiology Series: Polycythemia Vera Forecast in 27 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Polycythemia Vera in 27 Major Markets Polycythemia Vera (PV), also known as erythraemia, erythrocytosis, erythrocytosis megalosplenica, ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease Statistics in the US

  • February 2017
    24 pages
  • Blood Disease  

    Hospital  

    Intensive Care  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    10 pages
  • Blood Disease  

    Blood Supply  

  • United States  

View report >

Blood Disease Statistics in the US

  • February 2017
    8 pages
  • Blood Disease  

    Cytokine  

    Cancer  

  • United States  

View report >

Related Market Segments :

Blood Disease

ref:plp2013

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.